免疫组化与分子标志物在无特异性分子谱型子宫内膜癌中的预后作用:系统综述与Meta分析
该系统综述与Meta分析纳入14项回顾性研究共4654例无特异性分子谱型子宫内膜癌,评估L1细胞黏附分子、β-连环蛋白1、ARID1A、雌激素受体、孕激素受体及STMN1的预后价值。L1细胞黏附分子过表达显著预测复发和生存不良,雌激素受体阳性与复发风险降低和生存改善相关,孕激素受体表达缺失与复发增加和生存不良相关。
要点
- L1细胞黏附分子过表达显著预测复发和生存不良,雌激素受体阳性与复发风险降低和生存改善相关。
- 孕激素受体表达缺失与复发增加和生存不良相关。
- ARID1A和β-连环蛋白1突变及STMN1过表达未显著影响复发或生存结局。
核心结论
- L1细胞黏附分子过表达、雌激素受体阳性和孕激素受体状态在无特异性分子谱型子宫内膜癌中显示 considerable 预后相关性,值得考虑作为改善患者管理的潜在标志物,包括保留生育功能的方法。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南并在PROSPERO注册(CRD42024601035),检索Scopus、PubMed/MEDLINE、ScienceDirect和Cochrane Library(1994年1月至2024年12月)。
- 纳入14项回顾性研究,共4654例无特异性分子谱型子宫内膜癌。
- 使用纽卡斯尔-渥太华量表和预后研究质量工具评估方法学质量,采用GRADE方法评价证据确定性。
主要发现
- L1细胞黏附分子过表达显著预测更高的复发风险(HR=3.42;95%CI 1.86-6.29;P<.001)和更差的生存(HR=4.31;95%CI 2.62-7.09;P<.001)。
- 雌激素受体阳性与复发风险降低显著相关(HR=0.37;95%CI 0.26-0.53)和生存改善显著相关(HR=0.22;95%CI 0.17-0.29)。
- 孕激素受体表达缺失与复发增加和生存结局更差相关。
- ARID1A和β-连环蛋白1突变及STMN1过表达未显著影响复发或生存结局。
关键数值与推荐
- 纳入标准:评估L1细胞黏附分子、β-连环蛋白1、ARID1A、雌激素受体、孕激素受体和STMN1表达或突变状态在无特异性分子谱型子宫内膜癌中预后作用的研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: No specific molecular profile endometrial cancer represents nearly half of the diagnoses, characterized by substantial molecular heterogeneity and intermediate recurrence and survival outcomes. Currently, no immunohistochemical or molecular markers are established in guidelines to improve prognosis estimation and personalize treatment in no specific molecular profile endometrial cancer. This systematic review and meta-analysis aimed to evaluate the prognostic significance of potential immunohistochemical and molecular surrogate markers in no specific molecular profile endometrial cancers. DATA SOURCES: This systematic review and meta-analysis adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was registered with the International Prospective Register of Systematic Reviews (CRD42024601035). A comprehensive literature search was conducted using Scopus, PubMed/MEDLINE, ScienceDirect, and the Cochrane Library (January 1994-December 2024). STUDY ELIGIBILITY CRITERIA: Studies assessing the prognostic roles of L1 cell adhesion molecule, catenin beta 1, AT-rich interactive domain-containing protein 1A, estrogen receptor, progesterone receptor, and STMN1 expression or mutation status in no specific molecular profile endometrial cancers were included. STUDY APPRAISAL AND SYNTHESIS METHODS: Methodological quality was assessed using the Newcastle-Ottawa Scale and the Quality in Prognosis Studies tool for risk of bias in prognostic studies. Certainty of evidence for each outcome was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation approach. Hazard ratios for recurrence and survival were calculated using random-effects or fixed-effects models depending on heterogeneity. RESULTS: Fourteen retrospective studies including 4654 no specific molecular profile endometrial cancers were analyzed. L1 cell adhesion molecule overexpression significantly predicted higher recurrence (hazard ratio=3.42; 95% confidence interval, 1.86-6.29; P<.001) and worse survival (hazard ratio=4.31; 95% confidence interval, 2.62-7.09; P<.001). Estrogen receptor positivity correlated significantly with reduced recurrence risk (hazard ratio=0.37; 95% confidence interval, 0.26-0.53) and improved survival (hazard ratio=0.22; 95% confidence interval, 0.17-0.29). Loss of progesterone receptor expression was associated with increased recurrence and poorer survival outcomes. Conversely, AT-rich interactive domain-containing protein 1A and catenin beta 1 mutations and STATHMIN1 overexpression did not significantly impact recurrence or survival outcomes. CONCLUSION: L1 cell adhesion molecule overexpression, estrogen receptor positivity, and progesterone receptor status demonstrate considerable prognostic relevance in no specific molecular profile endometrial cancer, warranting consideration as potential markers for improving patient management, including fertility-sparing approach.
引用
- Ferrari F, Gozzini E, Torroni L, et al. Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2025. PMID: 41033387. doi:10.1016/j.ajog.2025.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。